Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRC Adjuvant Gastric Infusional Chemotherapy Trial
ISRCTN93793971Phase 3Completed
- Sponsor
- Medical Research Council
- Start
- Jun 1994
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of epirubicin, cisplatin and fluorouracil in gastric adenocarcinoma and esophageal adenocarcinoma (EAC) (2 arms), sponsored by Medical Research Council. Primary endpoints: Survival time, Disease-free survival and 2 more. Started Jun 1994; status: completed.
02
Drugs
epirubicincisplatinfluorouracil
03
Conditions
gastric adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on ISRCTN93793971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN93793971.